CGP60474 - CAS 164658-13-3
Catalog number: B0084-430557
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C18H18ClN5O
Molecular Weight:
355.82
COA:
Inquire
Targets:
PKC | VEGFR
Description:
CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics relative to ATP.
Purity:
>98%
Synonyms:
CGP-60474; CGP 60474
MSDS:
Inquire
InChIKey:
IYNDTACKOAXKBJ-UHFFFAOYSA-N
InChI:
InChI=1S/C18H18ClN5O/c19-14-3-1-4-15(12-14)23-18-22-9-6-16(24-18)13-5-8-21-17(11-13)20-7-2-10-25/h1,3-6,8-9,11-12,25H,2,7,10H2,(H,20,21)(H,22,23,24)
Canonical SMILES:
C1=CC(=CC(=C1)Cl)NC2=NC=CC(=N2)C3=CC(=NC=C3)NCCCO
1.Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.
Kuo GH;Deangelis A;Emanuel S;Wang A;Zhang Y;Connolly PJ;Chen X;Gruninger RH;Rugg C;Fuentes-Pesquera A;Middleton SA;Jolliffe L;Murray WV J Med Chem. 2005 Jul 14;48(14):4535-46.
On the basis of previous studies, we identified pyrazine-pyridine A as a potent vascular endothelial growth factor inhibitor and pyrimidine-pyridine B as a moderately potent cyclin dependent kinase (CDK) inhibitor. A proposed combination of CGP-60474 and compound B led to the discovery of [1,3,5]triazine-pyridine as a new series of potent CDK inhibitors. Palladium-catalyzed C-C bond formation reactions, particularly the Negishi coupling reaction, were used to assemble various triazine-heteroaryl analogues effectively. Among them, compound 20 displayed high inhibitory potency at CDK1 (IC(50) = 0.021 microM), CDK2, and CDK5 and submicromolar potency at CDK4, CDK6, and CDK7. Compound 20 also displayed high potency at GSK-3beta. It demonstrated potent antiproliferative activity on various tumor cell lines, including HeLa, HCT-116, U937, and A375. When 20 was administered intraperitoneally at 150 and 125 mg/kg to nude mice bearing human A375 xenografts, the compound produced a significant survival increase. Molecular docking studies were conducted in an attempt to enhance the understanding of the observed structure-activity relationship.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PKC Products


CAS 443913-73-3 Vandetanib

Vandetanib
(CAS: 443913-73-3)

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM.

CAS 137592-45-1 Bisindolylmaleimide II

Bisindolylmaleimide II
(CAS: 137592-45-1)

Bisindolylmaleimide II is a potent and ATP-competitive inhibitor of protein kinase C (PKC) (IC50 = 0.01 μM). It also displays an antagonistic effect on nicotini...

CAS 136194-77-9 GO-6976

GO-6976
(CAS: 136194-77-9)

GO 6976, also known as PD-406976, is a potent inhibitor of neurotrophin-receptor intrinsic tyrosine kinase. Gö 6976 blocked neurotrophin-induced signaling and ...

Ramucirumab
(CAS: 947687-13-0)

Ramucirumab is a human IgG1 monoclonal antibody developed by ImClone Systems Inc to treat solid tumors. It has been approved by FDA for the treatment of advance...

CAS 215543-92-3 SU5402

SU5402
(CAS: 215543-92-3)

SU5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor.

CAS 170364-57-5 Enzastaurin

Enzastaurin
(CAS: 170364-57-5)

Enzastaurin is a protein kinase C beta inhibitor with 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Binding to the ATP-binding site, enzastaurin select...

CAS 164658-13-3 CGP60474

CGP60474
(CAS: 164658-13-3)

CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics rela...

CAS 113731-96-7 PKC (19-36)

PKC (19-36)
(CAS: 113731-96-7)

PKC (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (IC50 = 0.18 μM).

CAS 15966-93-5 SU5408

SU5408
(CAS: 15966-93-5)

A potent, selective and cell-permeable inhibitor of VEGFR2 kinase(IC50= 70 nM) with little or no effect against receptors for platelet-derived growth factor, ep...

CAS 125314-64-9 RO31-8220

RO31-8220
(CAS: 125314-64-9)

Ro 31-8220 is a PKC-inhibitor, which inhibits stimulated fluid pinocytosis of human PMNs induced by the PKC-activators phorbol myristate acetate or diacylglycer...

CAS 690206-97-4 ZM306416

ZM306416
(CAS: 690206-97-4)

ZM306416 is a vascular endothelial growth factor receptor (VEGFR) antagonist.

Pseudo RACK1

Pseudo RACK1 is an activator of protein kinase C which is a family of protein kinase enzymes involved in controlling the function of other proteins through the ...

CAS 5812-07-7 SU 4312

SU 4312
(CAS: 5812-07-7)

SU 4312 is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 = 0.8 and 19.4 μM, respectively) wirth selectivity over EGFR and c-Src tyr...

Anlotinib Dihydrochloride
(CAS: 1360460-82-7)

Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenic activities, which was designed to ...

CAS 151342-35-7 Ro 32-0432 hydrochloride

Ro 32-0432 hydrochloride
(CAS: 151342-35-7)

Ro 32-0432 hydrochloride is a selective and orally active inhibitor of PKC displaying a 10-fold greater selectivity for PKC-&alpha (IC50 = 9.3 nM); and a 4-fold...

CAS 169939-93-9 Ruboxistaurin Hydrochloride

Ruboxistaurin Hydrochloride
(CAS: 169939-93-9)

Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-m...

CAS 120685-11-2 Midostaurin

Midostaurin
(CAS: 120685-11-2)

Midostaurin is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

CAS 165800-06-6 Zoledronic acid monohydrate

Zoledronic acid monohydrate
(CAS: 165800-06-6)

Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inh...

CAS 10537-47-0 Tyrphostin 9

Tyrphostin 9
(CAS: 10537-47-0)

Tyrphostin 9 is firstly designed as an EGFR inhibitor with IC50 of 460 μM, but is also found to be more potent to PDGFR with IC50 of 0.5 μM.

CAS 116700-36-8 H-9 dihydrochloride

H-9 dihydrochloride
(CAS: 116700-36-8)

H-9 dihydrochloride is a protein kinase inhibitor. It inhibits PKA (Ki = 1.9 μM), PKG (Ki = 0.9 μM), CaMK II (Ki = 60 μM), PKC (Ki = 18 μM), casein kinase I (Ki...

Chemical Structure

CAS 164658-13-3 CGP60474

Quick Inquiry

Verification code

Featured Items